补肾强督方加减治疗强直性脊柱炎的临床研究Clinical Research of Bushenqiangdu Decoction on Ankylosing Spondylitis
王昊,阎小萍,孔维萍,王建明,金笛儿,尹初元,付倩
摘要(Abstract):
目的观察补肾强督方对强直性脊柱炎患者的治疗作用。方法将患者分为两组,治疗组予补肾强督方加减治疗,对照组予补肾强督方加柳氮磺胺吡啶片治疗,疗程2个月。分析治疗组患者的临床特点,两组治疗前后进行了临床症状、体征、疾病活动性指标等疗效观察。结果患者男女比例约为4.77∶1,平均发病年龄(25.14±8.76)岁,HLA-B27阳性92.83%,骨质疏松、骨量减少总发生率71.32%。常用中药特点提示"寒温并用",按药物分类前3位为祛风湿药、活血化瘀药、补肾药,按归经分类前3位为肝经、肾经、脾经。经补肾强督方加减治疗后,患者的血沉、C反应蛋白较治疗前有明显下降,BASFI、BASDAI等相关指数亦有显著改善,印证了补肾强督方能减轻强直性脊柱炎患者的免疫炎症反应。结论补肾强督方可调节免疫功能,对抗骨质疏松,为治疗强直性脊柱炎的基本方药。并且长期服用安全性好,无毒副作用。
关键词(KeyWords): 强直性脊柱炎;补肾强督方;临床研究
基金项目(Foundation):
作者(Author): 王昊,阎小萍,孔维萍,王建明,金笛儿,尹初元,付倩
参考文献(References):
- [1]Van der Linden S,Valkenburg HA,Cats A,et al.Evaluationof diagnostic criteria for ankylosing spondylitis:a proposal formodification of the New York criteria[J].Arthritis Rheum,1984,27(4):361-368.
- [2]Calin A,Garrett S,Whitelock H,et al.A new approach todefining functional ability in ankylosing spondyljtis:the devel-opment of the bath ankylosing spondylitis functional index[J].J Rheumatol,1994,21(12):2281-2285.
- [3]Garrett S,Jekinson T,Kennedy LG,et al.A new approach todefining disease status in ankylosing spondylitis:the bathankylosing spondylitis disease activity index[J].J Rheumatol,1994,21(12):2286-2291.
- [4]Jones SD,Steiner A,Garrett SL,et al.The bath ankylosingspondylitis patient global score(BAS-G)[J].Br J Rheuma-tol,1996,1:66-71.
- [5]Anderson JJ,Baron G,van der Heijde D,et al.Ankylos-ingspondylitis assessment group preliminary definition ofshort-term improvement inankylosing spondylitis[J].ArthritisRheum,2001,44:1876-1886.